Analyser av ODI Pharma

Analyst Group Comment on ODI Pharma’s Announcement of Rights Issue

ODI Pharma announced on October 30th that the company has resolved to carry out a rights issue of approximately SEK 4.

ODI Pharma AB (”ODI Pharma” or the ”Company”) delivered another strong quarter during Q4-23/24 (broken fiscal year), further proving the col...

ODI Pharma published on August 29th the company’s Q4-report for 2023/2024, which showed a continued strong momentum.

ODI Pharma announced on June 25th that the company has completed a first delivery of products to the Swiss market, a new market for ODI Phar...

The third quarter was a breakthrough quarter for ODI Pharma AB (”ODI Pharma” or the ”Company”), with net sales amounting to SEK 13.

ODI Pharma published on May 30 the company’s Q3-report for 2023/2024, which showed a strong financial development.

Analyst Group has entered into an agreement with ODI Pharma on commissioned research, including e.